Evaluation of short- and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemiaEvaluation of short- and long-term response to treatment in GIMEMA protocol for acute myeloid leukaemia Peer-Reviewed Journal Publication Δημοσίευση σε Περιοδικό με Κριτές 2015-10-252010enAcute Myeloid Leukaemia (AML) is a haematologic malignancy. Despite of improvements in prognosis it is still a severe disease and only a minority of patients are cured. Recently, insights into specific cytogenetics and biological aberration involved in the leukaemogenesis process are the target of research. LAM-99P GIMEMA Protocol identifies treatment guidelines for AML in adults. A methodological approach is proposed, compounding different modelling techniques, to assess the prognostic relevance of clinical as well as biological markers with regard to clinical endpoint, such as the achievement of Complete Remission in the short-term and long-term survival taking into account competing risks.http://creativecommons.org/licenses/by/4.0/International Journal of Biomedical Engineering and Technology33-4329-348 Zervakis Michail Ζερβακης Μιχαηλ Kounelakis M. G. Manikis G. Iacobelli, Silvia Ardoino I. Boracchi P. Lisboa P.J.G. Inderscience Basic medical sciences Basic sciences, Medical Biomedical sciences Health sciences Preclinical sciences Sciences, Medical medical sciences basic medical sciences basic sciences medical biomedical sciences health sciences preclinical sciences sciences medical AML Acute Myeloid Leukaemia Survival analysis Competing risks Multinomial logistic regression SVM Support Vector Machines Long-term response Short-term response Leukaemia treatment LAM-99P GIMEMA Protocol Modelling Clinical markers Biological markers